Paul William Manley

USPTO Granted Patents = 63 (Patent Applications = 27)

CIPO Patents = 7

EPO Patents = 28 (Patent Applications = 16)

Average Co-Inventor Count = 3.1

ph-index = 13

Forward Citations = 552(Granted Patents)

Inventors with similar research interests:

Location History:

Basel, CH (1996 - 2013)
Arlesheim, CH (1999 - 2018)

Company Filing History:

Schering Aktiengesellschaft

patents

3 out of 1,206

Dana-farber-cancer Institute Inc.

University of Texas System

Gsf-international Research Institute for Environment and Health

11. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2018

Loading Chart...

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9896444 - Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2018-02-20),

2. 9458112 - Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2016-10-04),

3. 9340537 - Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2016-05-17),

4. 9315489 - Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2016-04-19),

5. 9278981 - Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2016-03-08),

6. 9163005 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2015-10-20),

7. 8829195 - Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 (2014-09-09),

8. 8829015 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2014-09-09),

9. 8673930 - Pyrimidylaminobenzamide derivatives for systemic mastocytosis (2014-03-18),

10. 8653093 - Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases (2014-02-18),

11. 8604045 - Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis (2013-12-10),

12. 8580806 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-11-12),

13. 8552002 - Compounds and compositions as protein kinase inhibitors (2013-10-08),

14. 8513256 - Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (2013-08-20),

15. 8445479 - Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity (2013-05-21),

Title: Paul William Manley: An Innovative Patent Holder from Arlesheim

Introduction:

In the world of innovation and patents, there are remarkable individuals who continuously contribute to advancements in various fields. One such individual is Paul William Manley, based in Arlesheim, Switzerland. With an impressive portfolio of 62 patents, Manley has made significant contributions to the pharmaceutical industry, particularly in the realm of ABL1, ABL2, and BCR-ABL1 inhibition.

Latest Patents:

Paul William Manley's latest patents revolve around benzamide derivatives for inhibiting the activity of ABL1, ABL2, and BCR-ABL1. These compounds, formulated under the chemical structure of formula (I), hold promise in the development of targeted therapies for the treatment of certain diseases. Such inventions highlight Manley's dedication to innovation and his commitment to improving the lives of patients.

Career Highlights:

Throughout his career, Paul William Manley has worked with renowned companies, such as Novartis AG and Schering Aktiengesellschaft. Novartis, a global pharmaceutical giant, is widely recognized for its groundbreaking research and development initiatives. Manley's association with Novartis reflects his exceptional expertise and contributions to the field of pharmaceuticals.

Collaborations:

In his professional journey, Paul William Manley has had the opportunity to collaborate with exceptional individuals who share his passion for innovation. Notably, he has worked alongside esteemed colleagues like Guido Bold and Pascal Furet. These collaborations have undoubtedly enriched Manley's approach to problem-solving and patent development, enabling him to tap into diverse perspectives and expertise.

Conclusion:

Paul William Manley, hailing from Arlesheim, Switzerland, has established himself as an exemplary patent holder within the pharmaceutical realm. With an impressive portfolio of 62 patents, Manley's contributions in the field of ABL1, ABL2, and BCR-ABL1 inhibition exemplify his passion for scientific innovation and commitment to improving healthcare outcomes. Collaborating with prestigious companies such as Novartis AG and Schering Aktiengesellschaft, alongside renowned colleagues like Guido Bold and Pascal Furet, further strengthens his contributions to the field. With each patent, Manley not only supports the development of novel treatments but also inspires future generations of inventors and innovators in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.